Reported 1 day ago
H.C. Wainwright has raised the price target for uniQure N.V. (QURE) from $70 to $110, maintaining a Buy rating due to positive results from the company's AMT-130 trials for Huntington’s disease. The stock has seen a remarkable increase of over 339% since the announcement, indicating the potential of AMT-130 to significantly alter the progression of the disease.
Source: YAHOO